<DOC>
	<DOCNO>NCT00154102</DOCNO>
	<brief_summary>Drugs use cancer work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Giving combination chemotherapy together cetuximab first treatment diagnosis metastatic colorectal cancer ( '1st-line ' treatment ) may improve treatment efficacy . However , yet know whether give combination chemotherapy together cetuximab effective combination chemotherapy alone . This open-label trial investigates effectiveness cetuximab combination standard effective chemotherapy ( 5-Fluorouracil ( 5FU ) /Folinic acid ( FA ) plus irinotecan ) metastatic colorectal cancer first-line setting , compare chemotherapy alone patient express epidermal growth factor ( EGF ) receptor . Patients express EGF Receptor randomly assign one 2 group either receive combination chemotherapy alone cetuximab ( open-label study ) treat progression disease unacceptable toxicity occur . Regular efficacy assessment ( every 8 week ) base imaging perform throughout study together regular safety assessment ( e.g . safety lab ) . An independent Safety Board expert also monitor safety data . After participant discontinuation trial , regular updates treatment survival status request investigator . The entire study ( first patient enter study last collect follow-up information ) 4-5 year long .</brief_summary>
	<brief_title>Cetuximab Combined With Irinotecan First-line Therapy Metastatic Colorectal Cancer ( CRYSTAL )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Diagnosis histologically confirm adenocarcinoma colon rectum Inoperable metastatic disease Immunohistochemical evidence epidermal growth factor receptor expression tumor tissue Presence least 1 bidimensionally measurable index lesion Previous irinotecanbased chemotherapy Previous chemotherapy colorectal cancer except adjuvant treatment terminate 6 month start study treatment Radiotherapy , surgery ( exclude prior diagnostic biopsy ) investigational drug 30 day start study treatment Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>cetuximab</keyword>
	<keyword>first-line treatment</keyword>
</DOC>